Bayer joins iia
The iia is pleased to welcome Bayer as it’s newest member, and have provided a few words to introduce themselves:
“At Bayer, our focus is to discover and develop medicines that provide the opportunity to live a healthier life.
That’s why we’re continually expanding our pipeline portfolio in oncology and cardiovascular care, developing new approaches using cell and gene therapy. Our portfolio also includes a long history of development in hematology and radiology.
We are bringing forth new treatments and making investments in many disease areas. Yet, our work doesn’t stop in the lab because innovation alone isn’t enough. Bayer is committed to addressing issues that create barriers to access optimal care. We know that every positive health outcome begins with a commitment to focus on the individual.”
To find out more, visit Bayer’s website by clicking here.